Overview

Open-Label, Extension Trial to Demonstrate the Effectiveness and Safety of L-CsA Plus Standard of Care in the Treatment of BOS in Patients Post Single or Double Lung Transplant

Status:
Enrolling by invitation

Trial end date:
2024-04-01

Target enrollment:

Participant gender:

Summary

Enrollment will be limited to patients who have completed 48 weeks participation in either the BT-L-CsA-301-SLT (BOSTON-1) or BT-L-CsA-302-DLT (BOSTON-2) trial. All patients in this clinical trial will receive L-CsA in addition to Standard of Care, regardless of randomization arm in prior trials.

Phase:

Phase 3

Details

Lead Sponsor:

Breath Therapeutics Inc.
Zambon SpA

Treatments:

Cyclosporine
Cyclosporins